000 01775nai a2200457 i 4500
999 _c276792
_d276792
001 on1056953910
003 OCoLC
005 20190109132926.0
006 m o d f
007 cr mn|||||||||
008 181015c20189999dcu x w obb f0 2eng c
010 _a2018231750
040 _aPUCPR
_beng
_erda
_epn
_cGPO
_dMvI
042 _apcc
043 _an-us---
074 _a0807-A-07 (online)
086 0 _aLC 14.23:R 45279/
099 _aLC 14.23:R 45279/
100 1 _aDuff, Johnathan H.,
245 1 0 _aBuprenorphine and the opioid crisis :
_ba primer for Congress /
_cJohnathan H. Duff.
264 1 _a[Washington, D.C.] :
_bCongressional Research Service,
_c2018-
300 _a1 online resource.
336 _btxt
337 _bc
_2rdamedia
338 _bcr
_2rdacarrier
490 1 _aReport / Congressional Research Service ;
_vR45279
500 _aThe CRS report home page provides access to all versions published since 2018.
500 _aReport includes illustrations.
500 _aCRDP Program record.
504 _aReport includes bibliographical references.
588 _aDescription based on latest iteration, viewed Oct. 15, 2018; title from CRS report home page.
710 2 _aLibrary of Congress.
_bCongressional Research Service,
773 0 8 _iContained in (work):
_tCRS reports (Library of Congress. Congressional Research Service)
_w(DLC) 2018231131
_w(OCoLC)1052784408
830 0 _aCRS report ;
_vR45279.
856 4 0 _uhttps://purl.fdlp.gov/GPO/gpo110058
650 0 _aBuprenorphine.
650 0 _aOpioid abuse
_zUnited States
_xPrevention.
650 0 _aDrug addiction
_xTreatment
_zUnited States.
650 0 _aBuprenorphine
_xCase studies
_vAbstracts.
942 _2sudocs
_c8